In the ongoing CRISPR patent battle, after four days of oral arguments, it was announced today that the European Patent Office's (EPO) Technical Board of Appeal (Board) upheld the earlier EPO Opposition Division ruling from January 2018, stating that Broad Institute's European patent EP2771468 is not novel and therefore fully revoked.
The Board confirmed the prior decision, finding that all claims of the Broad Institute's patent for gene editing were invalid because the Broad Institute was not entitled to its earliest priority dates and therefore the claims lacked novelty in light of prior art. Thus, all claims of the Broad Institute's patent remain fully revoked and the Opposition Division's decision to revoke the patent is now final.
The content of this article is intended to provide a general guide to the subject matter. Specialist advice should be sought about your specific circumstances.